The Latest Cardiac and Vascular News
Simultaneous Publication of Three Studies in the Journal of the American College of Cardiology: Cardiovascular Interventions SANTA CLARA, Calif., June 28, 2021 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to […]
New Technology Add-on Payment (NTAP) Included in Proposed Fiscal Year 2022 Rule SANTA CLARA, CALIF., April 27, 2021 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular […]
Announces Preliminary Revenue Range for the First Quarter of 2021 SANTA CLARA, Calif., March 30, 2021 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today […]
Establishes a Company to Maximize the Availability of IVL for the Chinese Population SANTA CLARA, Calif., March 22, 2021 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified […]
SANTA CLARA, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months and […]
Transformative Technology Now Available for Calcified Coronary Plaque SANTA CLARA, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that […]
SANTA CLARA, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended […]
Disrupt PAD III is Largest Randomized Study of Complex Patients Typically Excluded from Clinical Trials SANTA CLARA, Calif., Nov. 07, 2020 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) […]
Positive Disrupt CAD III Data Submitted to FDA in Premarket Approval Application SANTA CLARA, Calif., Oct. 15, 2020 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat severely […]
SANTA CLARA, Calif., July 20, 2020 (GLOBE NEWSWIRE) — Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that Maria Sainz has joined its Board of Directors […]
